5 Value Stocks In The Healthcare Sector
Portfolio Pulse from Benzinga Insights
The article highlights 5 value stocks in the healthcare sector, including Pfizer, First Wave BioPharma, Sensus Healthcare, Agile Therapeutics, and Revelation Biosciences. These companies have low P/E multiples, indicating they may be undervalued. However, investing in value stocks carries the risk that their undervalued position may not improve.
June 12, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Agile Therapeutics has a P/E of 0.03 and reported Q1 EPS of $-7.76, up from $-9.0 in Q4.
Agile Therapeutics' extremely low P/E ratio suggests it may be undervalued. However, its negative EPS indicates potential issues, and as a value stock, there is a risk that its undervalued position may not improve, leading to a neutral short-term price impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
First Wave BioPharma has a P/E of 0.01 and reported Q4 EPS of $-9.47, down 151.24% from Q3.
First Wave BioPharma's extremely low P/E ratio suggests it may be undervalued. However, its decreasing EPS indicates potential issues, and as a value stock, there is a risk that its undervalued position may not improve, leading to a neutral short-term price impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Pfizer has a P/E of 7.69 and reported Q1 EPS of $1.23, up 7.89% from Q4. Its dividend yield is 4.17%, up from 3.17% in the previous quarter.
Pfizer's low P/E ratio and increasing EPS and dividend yield indicate it may be undervalued. However, as a value stock, there is a risk that its undervalued position may not improve, leading to a neutral short-term price impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Revelation Biosciences has a P/E of 0.02 and reported Q1 EPS of $-0.51, up from $-1.77 in Q4.
Revelation Biosciences' extremely low P/E ratio suggests it may be undervalued. However, its negative EPS indicates potential issues, and as a value stock, there is a risk that its undervalued position may not improve, leading to a neutral short-term price impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Sensus Healthcare has a P/E of 7.76 and reported Q1 EPS of $-0.12, down from $0.17 in Q4.
Sensus Healthcare's low P/E ratio suggests it may be undervalued. However, its decreasing EPS indicates potential issues, and as a value stock, there is a risk that its undervalued position may not improve, leading to a neutral short-term price impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100